A Phase 1, Four-part, Fixed-sequence, Open-label Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Trial Profile

A Phase 1, Four-part, Fixed-sequence, Open-label Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs CC 90001 (Primary) ; Digoxin; Metformin; Midazolam; Nintedanib; Omeprazole; Rosuvastatin; Warfarin
  • Indications Idiopathic pulmonary fibrosis
  • Focus Pharmacodynamics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top